BlackRock’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-6,390,108
| Closed | -$115M | – | 5259 |
|
|
2020
Q2 | $115M | Buy |
6,390,108
+302,835
| +5% | +$4.21M | ﹤0.01% | 1751 |
|
|
2020
Q1 | $43.4M | Sell |
6,087,273
-127,170
| -2% | -$1.59M | ﹤0.01% | 2144 |
|
|
2019
Q4 | $148M | Sell |
6,214,443
-2,996
| -0% | -$82.6K | 0.01% | 1710 |
|
|
2019
Q3 | $167M | Buy |
6,217,439
+892,491
| +17% | +$25.1M | 0.01% | 1537 |
|
|
2019
Q2 | $144M | Buy |
5,324,948
+186,304
| +4% | +$5.84M | 0.01% | 1663 |
|
|
2019
Q1 | $178M | Sell |
5,138,644
-188,295
| -4% | -$5.43M | 0.01% | 1499 |
|
|
2018
Q4 | $104M | Buy |
5,326,939
+19,532
| +0.4% | +$402K | 0.01% | 1773 |
|
|
2018
Q3 | $141M | Buy |
5,307,407
+55,895
| +1% | +$1.82M | 0.01% | 1730 |
|
|
2018
Q2 | $198M | Buy |
5,251,512
+583,581
| +13% | +$22.3M | 0.01% | 1470 |
|
|
2018
Q1 | $152M | Sell |
4,667,931
-28,660
| -0.6% | -$1.26M | 0.01% | 1556 |
|
|
2017
Q4 | $229M | Buy |
4,696,591
+293,802
| +7% | +$14.9M | 0.01% | 1268 |
|
|
2017
Q3 | $238M | Buy |
4,402,789
+330,823
| +8% | +$19.4M | 0.01% | 1201 |
|
|
2017
Q2 | $229M | Buy |
4,071,966
+37,241
| +0.9% | +$1.49M | 0.01% | 1184 |
|
|
2017
Q1 | $158M | Buy |
4,034,725
+4,028,883
| +68,964% | +$128M | 0.01% | 1464 |
|
|
2016
Q4 | $131K | Sell |
5,842
-323
| -5% | -$6.31K | ﹤0.01% | 2391 |
|
|
2016
Q3 | $141K | Buy |
6,165
+908
| +17% | +$21.3K | ﹤0.01% | 2391 |
|
|
2016
Q2 | $124K | Buy |
5,257
+1,962
| +60% | +$48.4K | ﹤0.01% | 2408 |
|
|
2016
Q1 | $67K | Buy |
3,295
+1,471
| +81% | +$46.7K | ﹤0.01% | 2215 |
|
|
2015
Q4 | $94K | Buy |
1,824
+751
| +70% | +$36.4K | ﹤0.01% | 1796 |
|
|
2015
Q3 | $46K | Sell |
1,073
-128
| -11% | -$6.18K | ﹤0.01% | 1943 |
|
|
2015
Q2 | $54K | Sell |
1,201
-39
| -3% | -$1.57K | ﹤0.01% | 1949 |
|
|
2015
Q1 | $48K | Sell |
1,240
-184
| -13% | -$6.32K | ﹤0.01% | 1973 |
|
|
2014
Q4 | $40K | Buy |
1,424
+583
| +69% | +$16.2K | ﹤0.01% | 2058 |
|
|
2014
Q3 | $21K | Hold |
841
| – | – | ﹤0.01% | 2313 |
|
|
2014
Q2 | $25K | Buy |
841
+524
| +165% | +$12.7K | ﹤0.01% | 2270 |
|
|
2014
Q1 | $8K | Buy |
317
+60
| +23% | +$1.6K | ﹤0.01% | 2879 |
|
|
2013
Q4 | $7K | Hold |
257
| – | – | ﹤0.01% | 2948 |
|
|
2013
Q3 | $7K | Hold |
257
| – | – | ﹤0.01% | 2879 |
|
|
2013
Q2 | $6K | Buy |
+257
| New | +$5.11K | ﹤0.01% | 2983 |
|
BlackRock's PTLA Position: Q3 2020 in Review
BlackRock sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 6,390,108 shares — an estimated $115M sold.
BlackRock first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $238M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- BlackRock reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- BlackRock sold 6,390,108 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $115M.
- BlackRock first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- BlackRock's Portola Pharmaceuticals, Inc. position peaked at $238M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on BlackRock's 13F filing for Q3 2020, filed 6 Nov 2020.